[{"id":"447deee0-48df-4d5d-a0f4-8e3810a39c90","acronym":"DepiSCARRH","url":"https://clinicaltrials.gov/study/NCT03026998","created_at":"2021-01-18T14:53:55.583Z","updated_at":"2024-07-02T16:35:06.766Z","phase":"","brief_title":"MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)","source_id_and_acronym":"NCT03026998 - DepiSCARRH","lead_sponsor":"Institut Curie","biomarkers":" RB1","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 03/19/2017","start_date":" 03/19/2017","primary_txt":" Primary completion: 03/01/2034","primary_completion_date":" 03/01/2034","study_txt":" Completion: 03/01/2034","study_completion_date":" 03/01/2034","last_update_posted":"2024-04-30"},{"id":"70736adb-b060-44c5-baf0-08a2f859c924","acronym":"","url":"https://clinicaltrials.gov/study/NCT04471974","created_at":"2021-01-18T21:29:11.594Z","updated_at":"2025-02-25T16:10:30.954Z","phase":"Phase 2","brief_title":"ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04471974","lead_sponsor":"Rahul Aggarwal","biomarkers":" PD-L1 • RB1","pipe":" | ","alterations":" RB1 deletion • RB deletion","tags":["PD-L1 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Xtandi (enzalutamide) • ZEN-3694 • ZEN-3219"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-04-26"},{"id":"ee1f7ecf-9bc4-4111-8b8a-fd3789290137","acronym":"","url":"https://clinicaltrials.gov/study/NCT04926181","created_at":"2021-06-15T17:53:11.788Z","updated_at":"2024-07-02T16:35:07.351Z","phase":"Phase 2","brief_title":"Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer","source_id_and_acronym":"NCT04926181","lead_sponsor":"Rahul Aggarwal","biomarkers":" RB1 • SYP","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-04-26"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"}]